Raymond James Financial Services Advisors Inc. Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Raymond James Financial Services Advisors Inc. raised its holdings in Moderna, Inc. (NASDAQ:MRNAFree Report) by 2.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,338 shares of the company’s stock after purchasing an additional 1,554 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Moderna were worth $5,802,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Compagnie Lombard Odier SCmA raised its position in shares of Moderna by 5.1% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 136,593 shares of the company’s stock valued at $13,584,000 after purchasing an additional 6,616 shares in the last quarter. CX Institutional acquired a new stake in shares of Moderna during the 4th quarter valued at approximately $236,000. Jeppson Wealth Management LLC acquired a new stake in shares of Moderna during the 4th quarter valued at approximately $228,000. DMC Group LLC raised its position in shares of Moderna by 13.7% during the 4th quarter. DMC Group LLC now owns 7,716 shares of the company’s stock valued at $767,000 after acquiring an additional 927 shares in the last quarter. Finally, Strategic Investment Advisors MI raised its position in shares of Moderna by 128.7% during the 4th quarter. Strategic Investment Advisors MI now owns 14,587 shares of the company’s stock valued at $1,451,000 after acquiring an additional 8,208 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO James M. Mock sold 772 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $109.75, for a total transaction of $84,727.00. Following the completion of the sale, the chief financial officer now directly owns 3,632 shares of the company’s stock, valued at $398,612. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Insiders sold 65,021 shares of company stock valued at $6,847,342 over the last 90 days. 15.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MRNA shares. Canaccord Genuity Group upped their price target on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. HSBC reissued a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, March 28th. Finally, Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $129.82.

Get Our Latest Analysis on Moderna

Moderna Trading Down 2.3 %

Shares of MRNA stock opened at $101.21 on Thursday. The stock has a 50-day simple moving average of $99.23 and a 200 day simple moving average of $93.32. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $163.24. The stock has a market capitalization of $38.75 billion, a P/E ratio of -8.16 and a beta of 1.62. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter last year, the business posted $3.61 earnings per share. The company’s quarterly revenue was down 44.9% on a year-over-year basis. On average, sell-side analysts expect that Moderna, Inc. will post -7.48 earnings per share for the current fiscal year.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Recommended Stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.